T1	intervention 95 105	raloxifene
T2	outcome 893 921	breast cancer incidence rate
T4	control-participants 935 939	1000
T11	total-participants 652 656	3967
T12	eligibility 122 160	Postmenopausal women with osteoporosis
T13	intervention-participants 715 719	2280
T14	intervention-participants 780 783	401
T15	control 794 801	placebo
T16	control-participants 807 811	1286
T3	cv-bin-abs 926 930	5.39
T5	iv-bin-abs 989 993	2.26
T6	iv-bin-abs 1062 1066	3.59
